Antengene Corporation Limited (HKG:6996)
4.830
+0.130 (2.77%)
At close: Mar 27, 2026
Antengene Corporation Revenue
In the year 2025, Antengene Corporation had annual revenue of 105.34M CNY with 14.56% growth. Antengene Corporation had revenue of 52.16M in the half year ending December 31, 2025.
Revenue
105.34M CNY
Revenue Growth
+14.56%
P/S Ratio
27.99
Revenue / Employee
693.01K CNY
Employees
152
Market Cap
3.28B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.34M | 13.39M | 14.56% |
| Dec 31, 2024 | 91.95M | 24.65M | 36.62% |
| Dec 31, 2023 | 67.31M | -92.83M | -57.97% |
| Dec 31, 2022 | 160.14M | 131.37M | 456.62% |
| Dec 31, 2021 | 28.77M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 2.01B |
| AIM Vaccine | 1.38B |
| Qyuns Therapeutics | 897.99M |
| BioDlink International Company | 831.99M |
| Shandong Boan Biotechnology | 829.27M |
| Medtide | 546.29M |
| Mirxes Holding Company | 166.32M |
| Jiangsu Recbio Technology | 14.16M |
Antengene Corporation News
- 3 months ago - Antengene Secures Malaysian Approval For XPOVIO In Relapsed/Refractory DLBCL - Nasdaq
- 4 months ago - Antengene: NMPA Approves IND Application For Phase Ib/II CLINCH-2 Study With ATG-022 - Nasdaq